Blockchain Registration Transaction Record

Helus Pharma CEO to Speak at Canaccord Conference

Helus Pharma CEO Michael Halstead to present at Canaccord Growth Conference. Learn about HLP003 and HLP004 for depression and anxiety. Visit for details.

This news matters because it highlights Helus Pharma's ongoing efforts to develop innovative treatments for depression and anxiety, which affect millions worldwide. The company's participation in a major growth conference signals its commitment to transparency and investor engagement, providing stakeholders with insights into its clinical progress and strategic direction. As mental health challenges continue to rise, the advancement of novel therapies like HLP003 and HLP004 could offer new hope for patients and potentially reshape the treatment landscape, making this a significant development for both the company and the broader healthcare sector.